| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Walid Tajeddinn, Torbjörn Persson, Silvia Maioli, Javier Calvo-Garrido, Cristina Parrado-Fernandez, Takashi Yoshitake, Jan Kehr, Paul Francis, Bengt Winblad, Kina Höglund, Angel Cedazo-Minguez, Dag Aarslan. 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neuroscience letters. vol 594. 2015-09-14. PMID:25841787. |
our results indicate that appswe induced decreased 5-ht1b expression and 5-ht release, as well as increased maoa activity and 5-ht breakdown. |
2015-09-14 |
2023-08-13 |
mouse |
| Moe Igari, Hao-Wei Shen, Yoko Hagino, Setsu Fukushima, Yoshiyuki Kasahara, Klaus-Peter Lesch, Dennis L Murphy, Frank Scott Hall, George R Uhl, Kazutaka Ikeda, Nobuo Yaegashi, Ichiro Sor. Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment. Behavioural pharmacology. vol 26. issue 1-2. 2015-09-03. PMID:25485646. |
the present experiments examined serotonergic roles in meth-induced locomotor sensitization by assessing: (a) the effect of serotonin transporter (sert; slc6a4) knockout (ko) on meth-induced locomotor sensitization; (b) extracellular monoamine levels in meth-treated animals as determined by in-vivo microdialysis; and (c) effects of serotonin (5-ht) receptor antagonists on meth-induced behavioral sensitization, with focus on effects of the 5-ht1b receptor antagonist sb 216641 and a comparison with the 5-ht2 receptor antagonist ketanserin. |
2015-09-03 |
2023-08-13 |
mouse |
| Moe Igari, Hao-Wei Shen, Yoko Hagino, Setsu Fukushima, Yoshiyuki Kasahara, Klaus-Peter Lesch, Dennis L Murphy, Frank Scott Hall, George R Uhl, Kazutaka Ikeda, Nobuo Yaegashi, Ichiro Sor. Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment. Behavioural pharmacology. vol 26. issue 1-2. 2015-09-03. PMID:25485646. |
these experiments demonstrate that 5-ht actions, including those at 5-ht1b receptors, contribute to meth-induced locomotor sensitization. |
2015-09-03 |
2023-08-13 |
mouse |
| Asres Berhan, Alex Barke. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC psychiatry. vol 14. 2015-09-02. PMID:25260373. |
it is a selective serotonin (5-ht) 3a and 5-ht7 receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and inhibitor of serotonin transporters. |
2015-09-02 |
2023-08-13 |
Not clear |
| Connie Sanchez, Karen E Asin, Francesc Artiga. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & therapeutics. vol 145. 2015-08-31. PMID:25016186. |
vortioxetine, a novel antidepressant for the treatment of major depressive disorder (mdd), is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, 5-ht1b receptor partial agonist, 5-ht1a receptor agonist and serotonin (5-ht) transporter (sert) inhibitor. |
2015-08-31 |
2023-08-13 |
Not clear |
| Lars Edvinsson, Gro Klitgaard Povlsen, Hilda Ahnstedt, Roya Waldse. CaMKII inhibition with KN93 attenuates endothelin and serotonin receptor-mediated vasoconstriction and prevents subarachnoid hemorrhage-induced deficits in sensorimotor function. Journal of neuroinflammation. vol 11. 2015-08-07. PMID:25498987. |
it has been suggested that transcriptional upregulation of cerebral artery contractile endothelin (etb) and 5-hydroxytryptamine (5-ht1b) receptors play an important role in the development of late cerebral ischemia and increased vasoconstriction after subarachnoid hemorrhage (sah). |
2015-08-07 |
2023-08-13 |
Not clear |
| David Matuskey, Zubin Bhagwagar, Beata Planeta, Brian Pittman, Jean-Dominique Gallezot, Jason Chen, Jane Wanyiri, Soheila Najafzadeh, Jim Ropchan, Paul Geha, Yiyun Huang, Marc N Potenza, Alexander Neumeister, Richard E Carson, Robert T Maliso. Reductions in brain 5-HT1B receptor availability in primarily cocaine-dependent humans. Biological psychiatry. vol 76. issue 10. 2015-07-27. PMID:24433854. |
preclinical evidence implicates the serotonin receptor 5-hydroxytryptamine 1b (5-ht1b) in the effects of cocaine. |
2015-07-27 |
2023-08-12 |
human |
| Ligia Westrich, Nasser Haddjeri, Ouria Dkhissi-Benyahya, Connie Sánche. Involvement of 5-HT₇ receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents. Neuropharmacology. vol 89. 2015-07-15. PMID:25446573. |
vortioxetine is a multimodal antidepressant that inhibits 5-ht1d, 5-ht3, 5-ht7 receptor activity, 5-ht reuptake, and enhances the activity of 5-ht1a and 5-ht1b receptors. |
2015-07-15 |
2023-08-13 |
mouse |
| Laurent Tritschler, Daniela Felice, Romain Colle, Jean-Philippe Guilloux, Emmanuelle Corruble, Alain Michel Gardier, Denis Joseph Davi. Vortioxetine for the treatment of major depressive disorder. Expert review of clinical pharmacology. vol 7. issue 6. 2015-06-15. PMID:25166025. |
vortioxetine (brintellix(®), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-ht1a, 5-ht1b, 5-ht1d, 5-ht3, 5-ht7 receptors and the serotonin (5-ht) transporter (5-htt). |
2015-06-15 |
2023-08-13 |
Not clear |
| Elena Dale, Hong Zhang, Steven C Leiser, Yixin Xiao, Dunguo Lu, Charles R Yang, Niels Plath, Connie Sanche. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. Journal of psychopharmacology (Oxford, England). vol 28. issue 10. 2015-06-09. PMID:25122043. |
vortioxetine, a novel antidepressant with multimodal action, is a serotonin (5-ht)3, 5-ht7 and 5-ht1d receptor antagonist, a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist and a 5-ht transporter (sert) inhibitor. |
2015-06-09 |
2023-08-13 |
rat |
| Ashley Wallace, Alan L Pehrson, Connie Sánchez, David A Morila. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. The international journal of neuropsychopharmacology. vol 17. issue 10. 2015-06-02. PMID:24852131. |
vortioxetine, a novel, multimodal-acting antidepressant, is a 5-ht3, 5-ht7 and 5-ht1d receptor antagonist, a 5-ht1b receptor partial agonist, a 5-ht1a receptor agonist, and inhibits the 5-ht transporter. |
2015-06-02 |
2023-08-13 |
rat |
| Shengyuan Ding, Fu-Ming Zho. Serotonin regulation of subthalamic neurons. Reviews in the neurosciences. vol 25. issue 4. 2015-05-26. PMID:24717335. |
via activation of 5-ht1b receptors on the afferent terminals, 5-ht inhibits glutamatergic input to the stn, but the inhibitory effect on gabaergic input is smaller. |
2015-05-26 |
2023-08-13 |
Not clear |
| Shengyuan Ding, Fu-Ming Zho. Serotonin regulation of subthalamic neurons. Reviews in the neurosciences. vol 25. issue 4. 2015-05-26. PMID:24717335. |
third, 5-ht may regulate the stn glutamatergic output by activating presynaptic 5-ht1b receptors, thus reducing burst firing in target neurons. |
2015-05-26 |
2023-08-13 |
Not clear |
| S C Leiser, A L Pehrson, P J Robichaud, C Sanche. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. British journal of pharmacology. vol 171. issue 18. 2015-05-26. PMID:24846338. |
vortioxetine is a 5-ht3 , 5-ht7 , and 5-ht1d receptor antagonist, 5-ht1b partial agonist, 5-ht1a agonist, and 5-ht transporter inhibitor. |
2015-05-26 |
2023-08-13 |
rat |
| Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu, Maria Francesca Mor. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clinical practice and epidemiology in mental health : CP & EMH. vol 11. 2015-04-20. PMID:25893002. |
mechanism of action : vortioxetine has 5-ht3, 5-ht7 and 5-ht1d antagonists, 5-ht1b partial agonist and a 5-ht1a agonist and serotonin transporter inhibitor property. |
2015-04-20 |
2023-08-13 |
Not clear |
| Sudhakar Selvaraj, Danilo Arnone, Alessandra Cappai, Oliver Howe. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neuroscience and biobehavioral reviews. vol 45. 2015-04-16. PMID:24971825. |
the evidence for alterations in serotonin transporter availability or other serotonin receptors (5-ht1b; 5-ht1d; 5-ht3; 5-ht4; 5-ht7) is limited. |
2015-04-16 |
2023-08-13 |
Not clear |
| Monika Kloza, Marta Baranowska-Kuczko, Anna Pędzińska-Betiuk, Konrad Jackowski, Hanna Kozłowsk. [Serotonin hypothesis and pulmonary artery hypertension]. Postepy higieny i medycyny doswiadczalnej (Online). vol 68. 2015-03-25. PMID:24934532. |
5-ht mediates contraction of pulmonary vessels via 5-ht1b and 5-ht2a receptors. |
2015-03-25 |
2023-08-13 |
Not clear |
| H Yamanaka, C Yokoyama, H Mizuma, S Kurai, S J Finnema, C Halldin, H Doi, H Ono. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Translational psychiatry. vol 4. 2015-03-06. PMID:24399045. |
four rhesus monkeys underwent pet studies with two serotonin (5-ht)-related pet radioligands, [(11)c]az10419369 and [(11)c]dasb, which are highly selective for the 5-ht1b receptor and serotonin transporter (sert), respectively. |
2015-03-06 |
2023-08-12 |
monkey |
| H Yamanaka, C Yokoyama, H Mizuma, S Kurai, S J Finnema, C Halldin, H Doi, H Ono. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Translational psychiatry. vol 4. 2015-03-06. PMID:24399045. |
fenfluramine, a 5-ht releaser, significantly decreased 5-ht1b receptor binding, but no additional effect was observed when it was administered with ketamine. |
2015-03-06 |
2023-08-12 |
monkey |
| Chris A Oosterhof, Mostafa El Mansari, Pierre Blie. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. The Journal of pharmacology and experimental therapeutics. vol 351. issue 3. 2015-02-17. PMID:25225185. |
using electrophysiologic techniques, the present study assessed the in vivo action of brexpiprazole on serotonin (5-ht) receptor subtypes 5-ht1a, 5-ht1b, and 5-ht2a; dopamine (da) d2 autoreceptors, and α1- and α2-adrenergic receptors. |
2015-02-17 |
2023-08-13 |
Not clear |